Related Experiment Video
Updated: Jul 3, 2026
08:49
External Cephalic Version: Is it an Effective and Safe Procedure?
Published on: June 6, 2020
Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial
Sedigheh Borna1, Noshin Sahabi
1Department of Perinatalogy, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran. s_borna@hotmail.com
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|February 16, 2008
Summary
Vaginal progesterone after preterm labor arrest extended delivery time but did not decrease recurrent preterm labor. This treatment reduced respiratory distress and low birthweight in newborns.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Pharmacology in Pregnancy
Background:
- Women experiencing preterm labor arrested by tocolytic therapy face higher risks of recurrence.
- The effectiveness of maintenance tocolytic therapy post-arrest remains debated.
Purpose of the Study:
- To investigate if vaginal progesterone supplementation after preterm labor inhibition increases latency and reduces recurrence.
- To evaluate the impact of progesterone on pregnancy outcomes in women with threatened preterm labor.
Main Methods:
- A randomized trial involving 70 women with threatened preterm labor.
- Participants received either 400 mg vaginal progesterone suppositories daily or no treatment after labor arrest.
Main Results:
- The progesterone group showed a significantly longer mean latency to delivery (36.11 days vs 24.52 days).
- Significantly lower rates of respiratory distress syndrome (10.8% vs 36.4%) and low birthweight (27% vs 51.5%) were observed in the progesterone group.
- No significant difference was found in recurrent preterm labor rates (35.1% vs 57.6%) between groups.
Conclusions:
- Vaginal progesterone post-tocolysis is associated with longer delivery latency.
- This treatment did not significantly reduce the incidence of recurrent preterm labor readmissions.
- Progesterone use improved key neonatal outcomes, including reduced respiratory distress and low birthweight.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...